Author Archives: Eva Brysch, Head of Investor Relations & Corporate Communications, MetrioPharm


No Comments on “I think we have been convincing.”

A background interview on MetrioPharm’s Phase II study

Dr. Petra Schulz, Senior Manager Drug Development at MetrioPharm spoke to us about the ongoing Phase II clinical trial and the details of the current press release
Photo: © F. Edler

MetrioPharm’s lead compound MP1032 entered Phase II clinical testing in early March. How has the study gone so far?

Dr. Petra Schulz: The most important goal of a large Phase II study continues to be to test the safety of the drug, i.e. whether the patients tolerate it well. So far, nobody has had to discontinue the study after taking MP1032, which is a good signal. The other important objectives – proof of efficacy and the search for the optimal dosage – are still unknown, because at the moment the study is blinded.

This week there was a...

Read more

No Comments on Premiere in Lisbon

MetrioPharm presents mode of action of MP1032 at a scientific conference

The 19th Meeting of the Society for Free Radical Research International 2018 in Lisbon

What is the most important step in the development of a new drug? The successful completion of preclinical trials, the first clinical study in humans or the proof of efficacy in patients? All these steps are a precondition for approval; they show that the drug works...

Read more

No Comments on Inflammation, Alzheimer’s disease and a well-tested substance

What we can learn from our competitors

A recent study investigates the correlation between chronic inflammation and Alzheimer’s disease.
Foto: © Fotolia

In our last blog entry, our CEO Dr. Wolfgang Brysch replied to the question: “Does MetrioPharm have competition? You can find the full article here. In this article we take a closer look at a drug that has already been tested.

If a patient suffers from an autoimmune disease, for example psoriasis, his physician ...

Read more

No Comments on Ask the CEO – 1

10 years of MetrioPharm – which one was the most difficult?

Dr. Wolfgang Brysch

Dr. Wolfgang Brysch

Actually, it’s a routine question and I could have expected it. I was asked at our anniversary celebration last fall: “10 years of MetrioPharm – which one was the most difficult?” I had to think about that question for a moment. The year 2007 is not far in the past, still the difficulties of that time feel oddly distant now.

In 2008, right after the founding of the company, we were in...

Read more

No Comments on „I definitely can’t say anything about that.“

10 years of MetrioPharm – how was it for the team? We’re asking one of our very first employees. And our newest team member.

Dr. Beate Ludescher is Head of Regulatory Affairs. She joined MetrioPharm in 2007. Dr. Sara Schumann is a Project Manager for Research and Development, she joined the team in October 2017.

Dr. Beate Ludescher is Head of Regulatory Affairs. She joined MetrioPharm in 2007. Dr. Sara Schumann is a Project Manager for Research and Development, she joined the team in October 2017.
Photo: © Eva Brysch, 2018

You are at a party: how do you explain what you do for a living?

Dr. Beate Ludescher: Difficult, this is a struggle I have at...

Read more